Phase 3Withdrawn
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma
- Sponsor
- SecuraBio (Industry)
- Conditions
- Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma
- Interventions
- Duvelisib; Placebo; Rituximab; Bendamustine
- Ages
- adults, older adults
- Registry
- NCT02576275
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent non-Hodgkin lymphoma (iNHL).
Primary outcomes
- Progression-Free Survival (PFS)
History
Last registry update
Primary completion
Started
Registered